English | 简体中文 | 繁體中文 | 한국어 | 日本語
Sunday, 14 February 2021, 01:00 HKT/SGT
Share:
    

Source: Cofttek Holding Limited
Cofttek, China's Largest Manufacturer of PEA, Draws Attention of Investors

LUOHE CITY, China, Feb 14, 2021 - (ACN Newswire) - Cofttek Holding Limited, a Chinese pharmaceutical manufacturer, has recently drawn the attention of investors, following the U.S. introduction of the FDA drug ultramicronized Palmitoylethanolamide (PEA) for COVID-19 patients. Cofttek is China's largest manufacturer of ultramicronized Palmitoylethanolamide (PEA) raw materials. Following the U.S. news, orders at Cofttek have surged, and production capacity has been saturated.

Cofttek founder Dr. Zeng explained, "Following this FDA news, the share price of FSD Pharma (NASDAQ: HUGE), our main competitor in the USA, roared from $3 to $14 in a few days. As the largest PEA manufacturer in China, Cofttek has attracted similar attention from many investors in the industry."

About Palmitoylethanolamide (PEA): https://www.cofttek.com/product/544-31-0/

Palmitoylethanolamide (PEA), an endogenous (manufactured by the body) fatty acid amide, is emerging as a new agent in the treatment of pain and inflammation. As an endogenous agent, one that is also found in foods such as eggs and milk, no serious side effects or drug-drug interactions have been identified.

PEA is a naturally occurring fatty acid. It is similar to an endocannabinoid, which is one of a suite of molecules found in cannabis targeting CB2 receptors. CB2 receptors can modulate both inflammation and pain throughout the human body. COVID-19 is characterized by an over-exuberant inflammatory response that may lead to a cytokine storm, which is not a virus killer. But Cofttek believes it can mitigate that immune response, which can be fatal.

About Cofttek

Cofttek Holding Limited, founded in 2008, is a high-tech pharmaceutical biochemical enterprise, integrating production, R&D and sales. It is located in Luohe Chemical Industry Park, in Luohe City, Henan Province, and is committed to the research and development of advanced pharmaceuticals, providing innovative products and high-quality services for the pharmaceutical industry.

Media Contact:
Dr. Zeng, Cofttek Holding Limited
E: info@cofttek.com,T: 86 1390 2465871
Website: https://www.cofttek.com

Source: Cofttek Holding Limited


Topic: Press release summary
Source: Cofttek Holding Limited

Sectors: BioTech, Healthcare & Pharm
https://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

Cofttek Holding Limited Related News
June 15, 2021 11:00 HKT/SGT
Cofttek Announces Mass-Production and Supply of Urolithin A & B
More news >>
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575